Literature DB >> 17179820

Assessment of biochemical aspirin resistance at rest and immediately after exercise testing.

Oyku Gulmez1, Aylin Yildirir, Ugur Bal, Necibe Didem Konas, Alp Aydinalp, Ozlem Demir, Ilyas Atar, Cagatay Ertan, Bulent Ozin, Haldun Muderrisoglu.   

Abstract

Some aspirin-treated patients experience thromboembolic events, a phenomenon termed 'aspirin resistance', which may be clinical or biochemical by definition. Physical exercise is known to enhance platelet secretion and aggregability. To evaluate the presence of biochemical aspirin resistance at rest and immediately after exercise in individuals with stable coronary artery disease or coronary artery disease risk factors. We prospectively enrolled 101 patients who had received 100 or 300 mg/day enteric-coated aspirin for at least 7 days. Biochemical aspirin resistance (defined as normal collagen-epinephrine closure time < 165 s) was studied using the standardized platelet function analyzer. Of the 101 patients, 63 were aspirin sensitive both at rest and immediately after exercise, 18 exhibited biochemical aspirin resistance both at rest and after exercise, and 20 were aspirin sensitive at rest but exhibited biochemical aspirin resistance immediately after exercise. The results of exercise testing were similar in all three groups (each P > 0.05). Our results indicate that in almost 20% of the patients, aspirin did not seem to protect against exercise-induced platelet activation, despite the presence of aspirin sensitivity at rest. We did not, however, determine the extent to which the biochemical aspirin resistance noted in our study applied to clinical events.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17179820     DOI: 10.1097/MBC.0b013e328010bd26

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  1 in total

1.  Platelet hyperactivity during exercise leading to iterative coronary stent thrombosis: clinical implications.

Authors:  Olivier Ormezzano; Benoit Polack; Gérald Vanzetto; Mohamed Sahnoun; Jacques Machecourt
Journal:  J Thromb Thrombolysis       Date:  2010-07       Impact factor: 2.300

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.